Back to top
more

Nabriva Therapeutics AG (NBRV)

(Delayed Data from NSDQ)

$2.16 USD

2.16
1,618,904

+0.01 (0.47%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.16 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy

Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

uniQure (QURE) Moves 5% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nabriva Therapeutics AG (NBRV) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 25.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy?

Nabriva Therapeutics (NBRV) has been struggling lately, but the selling pressure may be coming to an end soon.

Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat

bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.

Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses

Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.

Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y

Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.

Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates

ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat

Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.

Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows

Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View

Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.

Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track

Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.

BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision

BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.

Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.

Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus

Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.